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ABSTRACT 
Background:  Black South African women are known to have a high usage rate of 
injectable contraceptives. Breast cancer is the second leading cancer after malignant 
cervical neoplasms in black South African women. There is evidence that sex 
hormones are associated with an increased risk of developing breast cancer. In the 
Western Cape, investigators suggested that injectable contraceptives, more 
specifically DMPA, may increase breast cancer risk. In another study conducted in the 
same province, a weak association between breast cancer and women taking 
combined oestrogen/progesterone oral contraceptives was found, though no risk 
associated with injectable progestogen contraceptives (DMPA) was confirmed. 
Study Objective: This study aimed to determine whether there is an association 
between hormonal contraceptive use and an increased risk of cancer of the breast. 
Methods: Data was obtained from an ongoing case control study set up by 
MRC/Wits/NHLS Cancer Epidemiology Research Group (CERG) in 1995 to 
investigate risk factors associated with cancer among the black population in 
Johannesburg. Data was processed using STATA, version8 and analysed using 
univariate, bivariate and multivariate unmatched logistic regression models. 
Results: There was evidence that an overall use of oral contraceptives increases the 
risk of breast cancer; cases (n= 221), controls :( n= 153), OR=2.01 (95% CI: 1.45, 
2.80), p<0.0001. 
There was evidence of an association between use of injectable contraception and the 
risk of breast cancer; cases (n=244), controls (n=202), OR=1.51(CI: 1.14, 2.01), 
p=0.004 
 v
 Surprisingly, no other use characteristic of either hormonal contraceptive method was 
statistically significantly associated with the risk of breast cancer in our dataset. 
The combined use of both oral and injectable contraception was associated with an 
increased risk of breast cancer, OR=1.68(1.21, 2.33), p =0.002. There was a strong 
effect modification (interaction) between oral contraceptive use and injectable 
progesterone associated with the risk of breast cancer, (p=0.008).  
 
Conclusion: After adjusting for all potential risk and confounding factors, as 
collected in the dataset, there was evidence of an association between combined oral 
contraceptive use and breast cancer. An association between cancer of the breast and 
overall use of injectable progesterone use was also established. There was evidence of 
association between the use of both hormonal contraceptive methods and an increased 
risk of breast cancer. However, whether these findings reflect the reality in terms of 
causal relationship or are the result of bias must be ascertained. 
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CHAPTER ONE: INTRODUCTION 
  
1.1 BACKGROUND INFORMATION 
 
Reproductive and hormonal factors are the most important well established risk 
factors for breast cancer.1,2  The link between breast cancer and oestrogen has been 
recognized for more than 100 years, since George Beatson showed that surgical 
removal of both ovaries - known as bilateral oophorectomy - was followed by the 
remission of breast cancer in premenopausal women.2   Many years later, numerous 
studies demonstrated that breast cancer risk was strongly associated with various 
hormonal factors, and furthermore, a high serum concentration of oestradiol was 
shown to be an important determinant of breast cancer risk.3  This finding was 
confirmed by numerous prospective studies that revealed that high blood levels of 
estradiol are related to an increased breast cancer risk in postmenopausal women 
exposed to hormone replacement therapy.3  Subsequently, further scientific evidence 
has implicated both endogenous and exogenous oestrogen in the pathogenesis of 
malignant breast neoplasms. Indeed, hormonal preparations containing oestrogen and 
progestogen have been used as contraceptives since the early 1960s and appeared to 
be linked to the rise of breast cancer noted worldwide since then.1, 2, 3   
 
The occurrence of malignant breast cancer is very rare in women before 25 years of 
age, increasing after menopause and declining in older women.4 The low incidence of 
breast cancer among elderly women coincides with a decline in circulating 
oestrogen.1,4 This observation confirms the role of reproductive hormones in the 
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occurrence of the disease. The risk is increased by early menarche, late menopause, 
late age at first childbirth, and low parity.1,2,34 All of these factors demonstrate the role 
of high concentrations of endogenous oestrogen, in particular free oestradiol, in the 
development of breast cancer.  
 
In addition, the risk of developing breast cancer may be increased by exogenous 
contraceptive hormones, either oral or injectable.5,6  The possible effects of hormonal 
contraceptives on the risk of developing breast malignancy have been a subject of 
intensive research in the developed world.1,2,3,4,5  The findings of many studies 
remain, however, controversial, and even contradictory.  
 
In South Africa, since the 1970s, injectable progestogen contraceptives (IC) and oral 
contraceptives (OC), both progestogen only and combined oestrogen/progestogen 
containing preparations, have been the most commonly used contraceptive methods 
by black women.6 More specifically, studies have shown that depot 
medroxyprogesterone acetate (DMPA; trade name Depo-Provera), an injectable 
progestogen contraceptive, was used more frequently and was taken for longer 
periods in South Africa than in any other country in the world.7  Indeed, South Africa 
presents with the highest prevalence of use, with 27% of black women aged 15-49 
estimated to be current users of injectable contraceptives.8 Recently, another 
injectable progestogen, norethisterone enanthate, has also been introduced and used in 
South Africa.7  
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1.2 LITERATURE REVIEW  
 
1.2. 1 INVASIVE BREAST CANCER:  
 
Invasive breast cancers are defined as proliferation of malignant populations of cells 
that have the capacity to invade through the basement membrane and, therefore, are 
capable of distant metastasis.9,10 Only primary invasive breast cancer arising from 
glandular components of the breast, ducts and lobules; such as  invasive duct 
carcinoma, invasive lobular carcinoma, medullary carcinoma, tubular carcinoma, 
mucinous  carcinoma or invasive papillary carcinoma  are considered as invasive 
breast cancer in this study.9,10 
 
1.2.2 RISK FACTORS FOR BREAST CANCER 
 
A number of risk factors for female breast cancer have been identified. These include  
genetic predisposition (a family history of breast cancer is a risk factor)3, benign 
proliferative breast disease (epithelial hyperplasia, sclerosing adenosis, small duct 
papilloma)9, increasing age (breast cancer is rare before the age of 25 years), length of 
reproductive life (risk increases with early menarche and late menopause),   parity 
(the risk of developing breast cancer is much higher in nulliparous than in 
multiparous), age at first child (the risk of breast cancer increases in women older 
than 30 years at the time of their first child’s birth)9, exogenous estrogens 
(postmenopausal hormonal therapy or oral contraceptives), obesity (increased risk in 
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postmenopausal obese women attributable to synthesis of estrogens in fat deposits)3, 
dietary fat and heavy smoking.3,9 
                         
1.2.3 BREAST CANCER IN AFRICA 
 
Cancer of the breast is by far the most common cancer affecting women worldwide, 
with an estimated 1.05 million new cases in the year 2000, accounting for 22% of all 
new cancers in women.11 In Africa, 59,000 new breast cancer cases were estimated in 
2000, corresponding to 18% of all cancers in women.11  However, information 
concerning breast cancer remains scarce on the  African continent, given that only six 
countries (Zimbabwe, Uganda, Algeria, Mali, South Africa and Gambia) have cancer 
registries that monitor and report the disease.11, 12, 13 Within each of these countries, 
the reported rates are lower than in Western countries. For example, in Algeria 
(Algiers), an age standardized incidence rate of 21.3 per 100,000 was reported in 
1999, compared to 74.4 and 92.1 per 100,000 for the United Kingdom and United 
States of America, respectively.12 The same trend of much lower reported rates than 
Western countries was observed in other sub Saharan African countries in the same 
year.12  Even in Zimbabwe, which has a good population-based registration system, 
the incidence and prevalence rates of breast cancer reported for the same period are 
lower than in Western populations.11,12,13,14    An age standardized incidence rate 
(ASIR) of 20.3 per 100 000 was recorded in Zimbabwe in 1999.11,14  Interestingly, in 
Bulawayo, 1963-1977, women registered with breast cancer had a higher level of 
literacy than women with other types of cancer.11,16    The lower incidence rates in 
Africa  are likely due in part to high parity, low age at first birth and late menarche, or 
may merely be the result of lack of medical facilities capable of diagnosing the 
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disease, as well as under-reporting due to the scarcity of registries - population-based 
registries in particular. However, it may also be a real effect of lower socio-economic 
status in Africa than in the rest of the world. This assumption concurs with the 
observed higher incidence rates in women of higher socio-economic status compared 
to lower social classes, and higher incidence rates in urban dwellers compared to 
women in rural areas.14 In almost all developing countries with relatively low 
incidence rates of breast cancer, the risk appears to be increasing, even though data 
remain sparse.11  
 
1.2.4 BREAST CANCER INCIDENCE IN SOUTH AFRICA 
 
Breast cancer incidence rates in black South African females are generally 
comparable with those reported elsewhere in developing countries.12,13 However, the 
South African National Cancer Registry (NCR) is only pathology based, which may 
lead to under-reporting of breast cancer cases in this country. The occurrence of breast 
cancer is very rare in black women before 30 years of age and thereafter the incidence 
steadily increases with increasing age.6, 7,12,13,15 Reported breast cancer incidence is low 
among women living in rural areas in South Africa. However, in urban areas, it 
remains one of the most frequent cancers among black females of childbearing age.6, 
12, 13  In 1998 and 1999, breast cancer reached an average ASIR of 18 per 100,000, as 
reported by the NCR.12 However, there is a strong suspicion that the incidence of the 
disease is underestimated, particularly in urban areas where Black South African 
women tend to embrace a Western lifestyle. The incidence of the disease still remains 
significantly lower in black compared to white, coloured and Indian South African 
women, who have ASIRs of 76.5, 49.8 and 49.6 per 100,000, respectively12.  The 
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relatively low incidence of breast cancer among black females might be the result of 
under-reporting, the protective effect of high parity, extensive breast-feeding and a 
low fat diet in this population.6,7, 8 
 
1.2.5 HORMONAL CONTRACEPTIVES: 
 
a. Injectable contraceptives: these are progesterone preparations, which are a class of 
female synthetic sexual hormones that have been used by millions of women around 
the world over the past 25 years. The injectable contraceptive such as Depo–Provera® 
and norethisterone are administered at three and two month intervals, respectively. 
These hormonal preparations have been used more commonly by black South African 
women.5,6,8  
 
b. Oral contraceptives: synthetic sexual hormone pills whose preparations include 
either progestogen only if they contain progestin molecules in each cycle, or a 
combination of oestrogen and progestogen in each cycle (i.e. a monophasic, 
multiphasic, or sequential formulation).5,6 They come in several trademark names. 
(Melodene, etc.)  
 
1.2.6 HORMONAL CONTRACEPTIVES AS A RISK FACTOR FOR BREAST 
CANCER IN BLACK SOUTH AFRICAN WOMEN 
 
Studies on the association between hormonal contraceptives and breast cancer among 
black South African women are rare, and their findings contradictory.  
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In a case control study of breast cancers in black and ’coloured’ women in Western 
Cape, South Africa, Baillie et al (1997) showed that black women used injectable 
progesterone for birth control more frequently and for longer time periods than other 
women world-wide.7 Based on experimental evidence and previous studies in the 
United States, the investigators suggested that “unopposed progestogen”, and more 
specifically DMPA, may increase breast cancer risk.7 
 
The same research question was investigated by Shapiro et al. (2000), in the same 
study population.6 An overall weak association between breast cancer and women 
taking combined oestrogen/progesterone oral contraceptives was found (Odds Ratio: 
OR =1.2). The association was strongest in young women under 35 (OR=1.7). They 
found no association within age categories, or with recency or duration of use. There 
was no risk associated with injectable progestogen contraceptives, particularly 
DMPA, even in those aged less than 35 at diagnosis.6  
Thus, despite the two large-scale studies described above, the possible role, if any, of 
hormonal contraceptives in the occurrence of malignant breast neoplasm among black 
South African women has not been resolved.6    
 
1.2.7 OTHER RISK FACTORS AND CONFOUNDING EFFECTS 
 
In a study of the association between an exposure (risk factor) and outcome (disease), 
confounding can occur when another exposure exists in the study population that is 
associated with both the exposure and the outcome being studied.17 Therefore, 
confounding is about alternative explanations. Confounding (from the Latin word 
‘confoundere’, to mix together) is the situation where the association between a risk 
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factor and a disease is entirely or partially due to another exposure.17,18,19 The most 
common concern over confounding is that it may create the appearance of a cause-
effect relationship that in reality does not exist (positive confounding) or the effect 
can work in the opposite way, resulting in the association between a risk factor and a 
disease appearing to be weaker than it really is (negative confounding).17,18,19 
Confounding is a nuisance effect that needs to be controlled because it distorts the 
association between a risk factor of interest and the health outcome under study.17,18,19  
 
Effect modification can be defined as a situation where the association between an 
exposure and an outcome is different for each level of the risk factor under study.18,19 
Effect modifier is not the same as confounder.17, 18, 19  It is a real effect, independent 
of study design and needs to be detected and reported. However, effect modification 
and confounding are often considered together because the techniques of stratification 
and regression models are useful for both. To determine whether a risk factor is a 
confounder or an effect modifier, one must test whether the odds ratios can be 
considered to be constant over the strata.17,18 This is done by performing tests of 
homogeneity. For that purpose, the most commonly used is the Mantel-Haenszel Chi 
Square test of homogeneity.18, 19 
 
This study examined a number of potential confounders and other potential 
independent risk factors that were suspected to play a role in the relationship between 
hormonal contraceptive and cancer of the breast. The main objectives were to 
determine whether there is a relationship between different patterns of hormonal 
contraceptives use (overall contraceptive use, time since first use, duration of use, and 
time since last use) and cancer of the breast while controlling for potential 
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confounders and other well known risk factors that were available in the dataset, such 
as age, age at menarche, age at menopause, age at first pregnancy, parity, socio-
economic status and smoking.7,20,21,22,23,24,25  Logistic regression models were used to 
control for the possible confounding effects of these independent risk factors for 
breast cancer.                                            
                                                                                                                                                                         
1.2.8 Problem statement 
 
Breast cancer is one of the most common cancers affecting South African women of 
all races.12,13 Among black South African women, breast cancer is the second most 
prevalent cancer after malignant cervical tumours, accounting for an average of 39% 
of all cancers diagnosed in this population group, and claiming lives of many black 
females of middle and childbearing age.12,13  Thus, breast cancer is clearly a public 
health problem in black females, a population group known for its high use of 
hormonal contraceptives.6,8 Indeed, in spite of scientific evidence incriminating 
oestrogen in the physiopathology of breast cancer, and some studies suggesting a 
possible increased risk associated with hormonal contraceptives, injectable or oral 
contraceptives remain the most widely used contraceptive method by black South 
African women.1,2,6,8  The possible role of hormonal contraceptives in the occurrence 
of malignant breast neoplasm among black South African women has not been 
resolved, and only two studies have examined this question.6  ,8 
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I.2.9 Justification for the study  
 
The only key to surviving breast cancer remains early detection and appropriate   
treatment including surgical procedure, chemotherapy, hormonotherapy and 
radiotherapy. Various screening programs, including mammography and ultrasound 
examinations, exist in South Africa. However, the screening techniques and treatment 
procedures are an expensive way to fight this deadly disease on large scale, and are 
therefore unaffordable to a large proportion of black South African women. Thus, it is 
of utmost importance to identify and understand the preventable risk factors for breast 
cancer, so as to plan and implement valuable epidemiological preventive programs 
and thus reduce the incidence of this deadly disease. 
 
Numerous epidemiological studies conducted worldwide have revealed that hormonal 
contraceptive use and reproductive factors play a role in the development of breast 
malignancy.2 ,3,5,6 8  However, few studies so far have examined in depth the role of 
hormonal contraceptives in general, and injectable progesterone in particular, in the 
development of breast cancer in black South African women.6,8  Despite  large-scale 
studies carried out in the Western Cape, the possible role, if any, of oral and injectable 
contraceptives in the occurrence of malignant breast neoplasm among black South 
African women has not been definitely established.8 Clearly, further studies are 
needed to clarify any association between exposure to hormonal contraceptives and 
the development of breast cancer in this unique population, with its unique socio-
demographic characteristics. In particular, no such study has been conducted in 
Johannesburg, the most populated South African city; providing justification for the 
current project. Information on the association between hormonal contraceptive use 
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and breast cancer risk in black South African women is therefore needed to inform 
public health policies of this country. 
 
 
1.2.10 Hypothesis 
 
1.2. 10.1 Null Hypothesis 
 
There is no association between hormonal contraceptive use and the risk of breast 
cancer in black South African women attending tertiary hospitals in Gauteng. 
 
1.2.10.2 Alternative Hypothesis 
 
There is an association between hormonal contraceptive use and the risk of breast 
cancer in black South African women attending tertiary hospitals in Gauteng. 
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CHAPTER TWO: AIM AND STUDY OBJECTIVES      
            
2.1 Aim of the study  
To measure the association between hormonal contraceptives and the risk of breast 
cancer in black South African women attending tertiary hospitals in Gauteng. 
 
2.2 Specific objectives: 
a. To measure the association between injectable hormonal contraceptive (IC) use and 
the risk of breast cancer in black South African women 
b. To measure the association between oral contraceptive (OC) use and the 
development of breast cancer in black South African women. 
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CHAPTER THREE: MATERIALS AND METHODS 
 
This project entailed analysis of pre-existing data from an ongoing case-control study, 
which was initiated in 1995 in the three main public tertiary hospitals of Gauteng 
province, a predominantly urban province in South Africa. The study aimed at 
collecting data on potential risk factors for cancer in the black population of Greater 
Johannesburg (Johannesburg and Soweto). The background assumption was that since 
the vast majority of black residents of Johannesburg used public hospitals at that time, 
patients diagnosed with cancer in the referral hospitals would be representative of the 
black population as whole. 
 
3.1 Study design 
The dataset used in this project was obtained from a case control study carried out 
among black cancer patients admitted to Chris-Hani-Baragwanath, Hillbrow and 
Johannesburg General Hospital. The study began at Chris-Hani-Baragwanath in 
March 1995. In September of that year, the investigation expanded to include the 
Radiation Oncology facility at Hilllbrow hospital and the Medical Oncology Unit at 
Johannesburg hospital. From 1 November 2001, the study has only been conducted at 
Johannesburg General Hospital. Registered nurses trained in interview techniques 
questioned black patients aged 18 and older who presented with newly diagnosed 
cancers at the target hospitals. The interview was carried out using the patient’s first 
language. Informed written or verbal consent was sought and obtained from the 
patients before their participation in the investigation. The data collected included 
socio-demographic characteristics, reproductive and hormonal contraceptive use 
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history. Confidentiality and anonymity of study participants was assured. Cancer 
diagnosis was confirmed by histology, haematology, or cytology.  
 
For this research project, cases were selected from the overall database as black 
women, aged between 18 and 75 years, who presented with newly diagnosed 
invasive, parenchymal breast cancers at the target hospitals. Thus, breast ductal, 
lobular carcinoma in situ and breast skin cancers were not considered among cases. 
The controls were women, aged 18 to 75 years and diagnosed with cancers considered 
to be unrelated to hormonal contraceptive use. Furthermore, gynaecological 
malignancies were excluded because they may have similar risk factors to breast 
cancer. Thus, cancers of the vulva, uterine cervix, endometrium and ovary were not 
considered in the study. Cancers that were included in the control group originated 
from the following organs and systems: oesophagus, haematopoietic and reculo-
endothelial system,  colorectal region, lymph nodes, skin, lungs, bones, soft tissues, 
oral cavity, stomach, endocrine system, hepatobiliary system ,oto-rhino-laryngeal 
tract, pancreas, kidneys and lower urinary system, central nervous system, lower 
limbs ,eye and adnexa. 
 
3.2 Study population 
The study population consists of 6,363 black women aged 18 years and older, 
admitted with newly diagnosed cancers to the Chris-Hani-Baragwanath, Hillbrow, 
and Johannesburg hospitals from March 1995 to June 2004. These Government 
referral hospitals serve a large proportion of black women living in Greater 
Johannesburg (Johannesburg and Soweto) and black patients seen in those tertiary 
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medical institutions might be representative of a large proportion of black South 
African women of the same age groups. 
 
3.3 Study sample 
The study sample consists of 1,608 women. There were 753 cases and 855 controls, 
aged 18 years and older, obtained from the data set of this ongoing cancer case-
control study over the period extending from March 1995 to June 2004.  
 
3.4 Data analysis 
Data were cleaned in Excel and processed using STATA, version 8. Invasive breast 
cancer cases and controls were classified according to the International Classification 
of Diseases for Oncology (ICD-O), 2nd edition. Breast Carcinomas in situ were 
excluded. Cases and controls were coded as 1 and 0, respectively. Similarly, hormonal 
contraceptive use was coded as follows: never use as 0, oral contraceptive use only as 
1, injectable contraceptive use only as 2 and both oral and injectable contraceptives 
use as 3. Thorough cleaning of the dataset with regard to reproductive and socio-
demographic variables of interest was carried out in Excel, and data was thereafter 
transferred to STATA for analysis. The reliability and consistency of reproductive 
factors were checked among cases and controls. For example, if the age of the 
respondent was less than the age at menarche, then age at menarche was set as a 
missing value. Similarly, if reported age at first birth was less than age at menarche 
then age at first birth was set as missing value. The fertility age interval was 
considered to be 15-49 according to the international demographic standard.26  
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Age at first childbirth was not available in the overall dataset and calculated by 
subtracting the age of the oldest child from the age of the mother. Similarly, time 
since first and last use of either hormonal contraceptive method were respectively 
obtained by subtracting the age at which women first used hormonal contraceptives or 
the age when they stopped using them from the age of the respondent. Some of the 
socio-demographic characteristics were measured by proxy. Thus, socio-economic 
status was measured by proxy using the level of education, area of birth and type of 
house. 
The exposure of interest; hormonal contraceptive use and its related patterns were 
categorised and recorded in STATA.  Likewise, potential confounders and other risk 
factors of interest were also categorised and recorded. Both univariate (frequency), 
bivariate (chi square statistical test through cross-tabulation) and multivariate logistic 
statistical analyses were carried out. The variables assessed in relation to invasive 
breast cancer were overall oral and injectable contraceptive use and their different 
patterns of use - such as age at first use, the duration of use, time since first use as 
well as time since last use of each of the hormonal contraceptive methods. 
 
A frequency distribution of the controls and the distribution of reproductive and 
socio-demographic characteristics among cases and controls were produced using 
univariate analysis. This was followed by bivariate analysis aimed mainly at 
ascertaining whether there was statistical association between exposure of interest and 
the outcome. In addition, bivariate analysis was used to identify reproductive and 
socio-demographic factors that are statistically significantly associated with both the 
outcome and the exposure of interest. 
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Lastly, multivariate logistic analyses were conducted in order to measure the strength 
of any possible association between hormonal contraceptive use patterns and breast 
cancer. Multivariate analyses were adjusted for all reproductive and socio-
demographic variables that were found statistically significantly associated with both 
the exposure and the outcome at the 5% significance level in bivariate analyses. 
Logistic regression model, the stratified analysis by combined Mantel-Haenszel 
method and its associated test of homogeneity were used to assess effect modification. 
Reproductive and socio-demographic variables that showed a borderline significance 
level (slightly greater than 5%) were also included in multivariate analysis. 
 
3.5 Ethical consideration 
The University of Witwatersrand Committee for Research on Human Subjects 
(medical) approved the use of the case-control study data for this MSc project (ethics 
approval number: M050925). Written permission to analyze the data was obtained 
from the MRC/NHLS/Wits Cancer Epidemiology Research Group. 
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CHAPTER FOUR: RESULTS  
  
 
4.1 Univariate analysis 
Univariate analysis presents the distribution and measure of spread of the 
characteristics of interest among cases and controls.  
Table 1 shows the distribution of cancers in the control group. A total of 855 cancer 
types were selected. They were grouped into 20 types of malignancy according to the 
anatomical systems or specific organs from which they arose.                               
Cancer of the oesophagus was the most common cancer among controls (21.70%), 
followed by cancers of the haematopoietic and reticulo-endothelial system (14%), 
colorectal cancer (8.98%), lymph node cancers (7.93%) and malignancies originating 
from the skin (7.58%). Cancer of the eye and adnexa were the least commonly 
represented cancers among the controls (0.35%). 
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Table 1: Distribution of cancers in the control group 
 
Origin of cancer Frequency Percentage (%) 
Oesophagus 185 21.70 
Haematopoietic and 
Reticulo-endothelial system 119 14.00 
Colorectal 77 8.98 
Lymph nodes 68 7.93 
Skin 65 7.58 
Lungs 54 6.30 
Bones, joints and soft tissues 50 5.83 
Oral cavity 45 5.25 
Stomach 44 5.13 
Endocrine glands 30 3.50 
Sinus,pharynx,larynx 26 3.03 
Hepatobiliary tract 24 2.80 
Pancreas 16 1.87 
Kaposi sarcoma 12 1.40 
Lower urinary tract 10 1.17 
Salivary glands 9 1.05 
Kidney 7 0.82 
Central nervous system 7 0.82 
Ill defined sites (pelvis-lower 
limbs) 4 0.47 
Eye and adnexa 3 0.35 
Total 855 100 
 
 
Figure 1 shows the age distribution among cases and controls. The highest proportion 
of breast cancer cases occur in age group 40 to 49 (30.4%), followed by age group 50 
to 59 (28.1%). Case respondents in the age group 15 to 19 years contributed the smallest 
proportion of cases participants (0.1%). The age distribution curve among controls was 
shifted to the right - in contrast to cases, the highest proportion of controls were in age 
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group 50 to 59 (29.3%). Women in the control group aged less than 20 years represented 
the smallest proportion (0.4%) of respondents. The age range was similar for cases and 
controls (19 to 75 and 18 to 75 years, respectively). The mean age of cases (52, SD 10.9) 
was significantly younger than that of controls   (54, SD 12.7); p=0.0013. 
 
 Table 2 shows the distribution of reproductive characteristics among cases and controls.   
There was no significant difference at the 5% level between cases and controls with 
respect to the following reproductive characteristics normally associated with breast 
cancer (comparison of mean by Student test and test of proportions): The distribution of 
age at menarche among case subjects showed that the majority of women (63.8%) had 
their first menstrual period between 15 and 19 years. This was also the most common 
age group for menarche in the control group (66.6% aged 15 to 19 years). The mean age 
at menarche of cases and controls was 15.7 (SD 6.1) and 15.9 (SD 7.4), respectively. 
 
The percentage of cases and controls who reported ever having being pregnant was 
94.9% and 93.5%, respectively. The distribution of age group at first birth revealed 
that the majority (60%) of women in both groups had their first child in age groups 
20-29 and 30-39 years. The mean age at first childbirth and its corresponding standard 
deviation among the cases and controls was 31.4 (10.1) and 31.2 (10.4) years, 
respectively. With regard to the parity of study participants, the nulliparous 
constituted 1.9% of the cases study participants and 1.5% of the controls group. In 
each study group, 2.9% of the women had their last periods at ages between 28 and 39 
years.  
 However, the majority of cases and controls experienced the menopause when they 
were aged 46 years and above (45.2% and 53.5%, respectively). The age ranges at 
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menopause among cases and controls were 30-64 and 28-63 years, respectively. The 
mean age at menopause was 48.8 (SD 5.1) for the cases and 48.8 (SD 4.9) for the 
control participants. 
 
                               Figure1: Age distribution of cases and controls 
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Table 2: Description of reproductive characteristics among cases and controls 
 
 
Reproductive characteristics Breast cancer cases 
N (%)* 
Controls 
N (%)* 
   
  Age at menarche 
  10-14 
  15-19 
  ≥20 
 
 Ever pregnant 
 Yes 
 No 
 
 Age at first birth 
 15-19 
 20-29 
 30-39 
 40-49 
 
Parity 
 0 
 1-2 
 3-5 
 ≥6 
 
Age at menopause 
 28-39 
 40-49 
 ≥50   
 
 
256(32.5) 
502(63.7) 
20(2.1) 
 
 
747(94.9) 
39(5.1) 
 
 
102(13.5) 
244(31.3) 
242(30.8) 
184(19.0) 
 
 
14(1.9) 
205(27.2) 
179(23.8) 
51 (6.8) 
 
 
22(2.9) 
192(24.5 ) 
222(29.5) 
 
 
 
264(29.5) 
595(66.7) 
23(1.9) 
 
 
836(93.3) 
53(6.7) 
 
 
144(16.2) 
255(29.3) 
267(30.3) 
215(19.6) 
 
 
11(1.3) 
220(25.7) 
240(28.0) 
79(9.2) 
 
 
24(2.9) 
248(28.9) 
310(36.2) 
 
 
* Because of very few missing responses with regard to some of the variables, the total  
percentages do not attain, but approach nearly 100% among cases and controls 
 
 
Figure 2 shows the distribution of educational level among cases and controls. The mean 
level of education was significantly higher among cases (standard 8, SD 3.7) than 
among controls (standard 7, SD 3.8); p<0.00001. Cases and controls who reached 
between 8 and 11 years of schooling constituted the highest proportion; 42.4% and 
42.7%, respectively. In contrast, 34.4% of case respondents attained 12 years of 
education or higher compared to 24.5% of the controls.  
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In contrast to education level, analysis of variance (by one way ANOVA command) 
demonstrated that there was no significant difference between cases and controls (5% 
level) with regard to the following socio-demographic characteristics: smoking status, 
marital status, urban vs rural area of birth, number of sexual partners and type of 
house (brick or cement). Table 3 shows the distribution of socio-demographic 
characteristics among cases and controls.  
 
Figure 2: Distribution of education level among cases and controls 
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Table 3: Description of socio-demographic characteristics among cases and 
controls 
 
Characteristics                     Type of cancer 
Breast cancer 
N (%)*
Control 
N (%)* 
     
Smoking status 
 Never 
 Past smoker  
 Current smoker 
 
Marital status 
 Single 
 Married 
 Widowed 
 Separated 
 
Area of birth 
 Rural 
 Urban 
 
Number of partners 
 Single 
 Multiple 
 
House made of 
 Other materials 
 Brick/cement 
    
 
 
613(81.4) 
78(10.4) 
56(7.4) 
 
 
203(26.9) 
321(42.6) 
149(19.8) 
79(10.5) 
 
 
352(46.7) 
393(52.2) 
 
 
87(11.6) 
645(85.7) 
  
 
122(16.2) 
631(83.8) 
 
 
 
648(75.6) 
130(15.2) 
77(9.0) 
 
 
203(23.7) 
363(42.4) 
198(23.1.5) 
90(10.5) 
 
 
455(53.1) 
390(45.5) 
 
 
108(12.6) 
699(83.6) 
 
 
135(15.8) 
720(84.0) 
 
 
* Because of very few missing responses with regard to some of the variables, the total of the 
percents do not attain but approach nearly 100% among cases and controls. 
 
 
Tables 4 and 5 describe different patterns of hormonal contraceptive use among cases  
and controls. The exposure under investigation is hormonal contraceptive use and 
cancer of the breast is the outcome of interest. The age range for starting hormonal 
contraceptive use among our study participants was found to be between 14 and 50 
years. 
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A higher proportion of controls did not use any hormonal contraceptive method 
(570/855=66.7%), compared to women with breast cancer (389/753=51.7 %).  
 
With regard to oral contraception among our study participants, the proportion of 
cases (221/753=29.3%) who used oral contraceptives (including those who also used 
injectable contraceptives) was higher than the proportion of controls 
(153/855=17.9%) who used the same hormonal contraceptive method. Further 
analysis revealed that among cases and controls, women who used solely oral 
contraceptives represented 15% (113/753) and 8.5% (73/855), respectively, 
(p<0.0001).  
 
There was, however, no significant difference (5% level) between cases and controls 
for the following oral contraceptive use related characteristics (comparison of mean 
by Student T test): age at first use, age at last use, time since first use, time since last 
use and duration of use.  
 
The mean age at starting oral contraceptive use was 24.6 (SD 6.8) in cases and 24.1 
(SD 6.8) among controls. The age range at starting use of OC among cases and 
controls was 15-48 and 14-45, respectively. In addition, proportion of women starting 
the use of oral contraception was highest in age group 20 to 29 among both study 
arms. This age segment represented 12.6% (95/753) of cases against 9.0% (77/855) of 
the control group.  
 
The mean age at last use of OC among cases and controls was 31.3 (SD 9) and 29.2 
(SD 7.7), respectively. The age range of the variable was 16-50 for cases and 17-50 
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for controls. Surprisingly, the same age group, 20 to 29 years constituted the highest 
proportion of study respondents with regard to their age at last use of OC. They 
constituted 8.6 %( 65/753) of cases and 7.3 % (62/855) of controls. 
 
 The mean time since first use of OC among cases and controls was 22.3(SD9.6) and 
21.4(SD11), respectively. Further results show that women who reported the time 
since their first use of OC at 10 years and beyond constituted the highest proportion of 
study respondents, representing respectively 23.1% (174/753) of cases and 13.7% 
(108/855) of controls. 
 
The mean time since last use of OC was 16.6(SD 10.4) for women with breast cancer 
and 16.5(SD10.7) for controls. The results also show that the highest proportion was 
found among cases and controls who presented the time since last use of OC of 10 
years or more; 16.1%(121/753) and 9.7% (83/855),respectively. 
 
The mean duration of use of OC among cases and controls was 8.5(SD15.5) and 
8.6(17.6), respectively 
 
There was a significant difference in the proportions of women who used injectable 
contraceptives (regardless of OC use or not) among breast cancer patients and 
controls. The proportion of women who used injectable contraceptives among cases 
was significantly higher than the proportion of controls who used ICs. This 
represented 32.4% (244/753) of cases compared to 23.6% (202/855) of controls 
(p=0.0001) who used ICs. Excluding women who, in addition, used oral 
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contraception, the number of cases and controls who used only injectable 
contraception dropped to 138 (18.3%) and 122(14.2%) respectively.  
 
There were differences between cases and controls for age at first use and age at last 
use of ICs, in contrast to what was found for OC use.  
The mean age at first use of ICs among cases was weakly significantly higher than 
among controls; 25(SD7.2) and 24(SD7) years, respectively (p=0.0485). The age 
range at first use of IC was 15-46 among cases and 15-47 in control participants. In 
addition, study participants who started using IC between 20 to 29 years constituted 
the highest proportions; 15.8% (119/753) of cases and 9.9% (85/855) of the control 
group.  
Similarly, the mean age at last use of IC among cases was significantly higher than 
the mean age at last use of IC among control subjects; 33(SD 8.4) and 30(SD8.5), 
respectively (p=0.0072). The age at last use ranged from 16 to 50 in the case group 
and 17 to 50 among controls. In contrast to OC use, cases who reported stopping IC 
use during the age interval 30-39 constituted the highest proportion (9.4%), while 
among controls, the highest proportion was found within age group 20 to 29. 
 
In contrast, there was no significant difference (5% significance level) between cases 
and controls for the following IC use related characteristics: mean time since first use, 
mean time since last use and mean duration of use.  
 
The mean time since first use was 18.5(SD9) and 18(9.5), respectively, for cases and 
controls. The mean time since last use of IC among cases and controls was 12.8(10.5) 
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and 12.9(SD9.7) while the mean duration of use of injectable contraceptive was 7.6 
(SD13.3) for cases and 7.2(SD14.7) among control participants.  
 
The proportion of breast cancer patients who used both oral and injectable hormonal 
contraceptive methods was significantly higher than the proportion of controls who 
used similar hormonal contraception; 13.9 %( 105/753) and 9.2 %( 79/855), 
respectively, (p=0.0041)  
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Table 4:  Description of oral contraceptive (OC) use among cases and controls 
 
Oral contraceptive use related patterns             Types   of cancer 
Breast cancer 
N (%) 
Controls 
N (%) 
Oral contraceptive use 
Never  
Oral contraceptive use(OC)** 
Oral and injectable contraceptive use(OCIC) 
 
Age at starting use of OC 
14-19 
20-29 
30-39 
40-50 
Unknown 
 
Age at last use of OC 
14-19 
20-29 
30-39 
40-50 
Unknown 
 
Time since first use of OC 
≤4 
5-9 
≥10 
Unknown 
 
Time since last use of OC 
≤4 
5-9 
≥10 
Unknown 
 
Duration of use of OC 
≤4 
5-9 
10-14 
15-19 
≥20 
Unknown 
 
 
 
528(70.1)* 
221(29.3) 
105(13.3) 
 
 
51(6.8) 
95(12.6) 
48(6.4) 
4(0.5) 
23(3.1) 
 
 
15(2.0) 
65(8.6) 
59(7.8) 
40(5.3) 
42(5.6) 
 
 
9(1.1) 
15(1.9) 
174(22.1) 
23(2.9) 
 
 
32(4.1) 
26(3.4) 
121(16.1) 
42(5.3) 
 
 
92(11.7) 
45(5.7) 
29(3.7) 
23(2.9) 
15(1.9) 
17(2.2) 
 
 
 
693(81.1)* 
153(17.9) 
79(9.3) 
 
 
33(3.8) 
77(9.0) 
23(2.7) 
4(0.5) 
16(1.8) 
 
 
6(0.7) 
62(7.3) 
41(4.6) 
14(1.5) 
30(3.5) 
 
 
12(1.4) 
18(2.1) 
108(12.6) 
16(1.8) 
 
 
27(3) 
14(1.6) 
83(9.7) 
30(3.5) 
 
 
72(8) 
41(4.6) 
16(1.8) 
9(1) 
8(0.9) 
8(0.9) 
 
 
* Because of very high proportions of cases and controls that have ever used any oral 
contraceptives, the percentages related to oral use characteristics are small and thus, their sum 
does not attain 100% 
** Oral contraceptive use: women who took oral contraceptives, including those who, in 
addition, used injectable contraception. 
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Table 5: Description of injectable contraceptive (IC) use among cases and 
controls 
 
 
Injectable contraceptive use related patterns                   Types   of cancer 
Cases 
N (%) 
Controls 
N (%) 
Injectable contraceptive use 
Never  
Injectable contraceptive use (IC)** 
Injectable and oral contraceptive use(OCIC) 
 
Age at first use of IC 
14-19 
20-29 
30-39 
40-50 
Unknown 
 
Age at last use of IC 
14-19 
20-29 
30-39 
40-50 
Unknown 
 
Time since first use of IC   
≥4 
5-9 
≥10 
Unknown 
 
Time since last use of IC 
0-4 
5-9 
≥10 
Unknown 
 
Duration of use of IC 
≤4 
5-9 
10-14 
15-19 
≥20 
Unknown 
 
 
502(66.7)* 
244(32.4) 
105(13.3) 
 
 
43(5.7) 
119(15.8) 
50(6.4) 
16(2.1) 
16(3.4) 
 
 
11(1.4) 
63(8) 
78(10.4) 
46(6.1) 
46(6.1) 
 
 
14(1.8) 
23(2.9) 
191(24.3) 
16(2.0) 
 
 
57(7.2) 
29(3.7) 
112(14.2) 
46(5.8) 
 
 
119(15.1 
44(5.6) 
29(3.7) 
23(2.9) 
8(1) 
21(2.7) 
 
 
644(75.3)* 
202(23.6) 
79(9.3) 
 
 
56(6.5) 
85(9.9) 
41(4.6) 
5(0.6) 
15(3.1) 
 
 
12(1.4) 
70(8.2) 
45(5.3) 
29(3.4) 
46(5.4) 
 
 
15(1.7) 
28(3.1) 
145(16.2) 
15(1.7) 
 
 
45(5) 
20(2.2) 
92(10.3) 
46(5.1) 
 
 
99(12.6) 
49(5.5 
14(1.6) 
9(1) 
9(1) 
23(2.6) 
 
 
* Because of very high proportions of cases and controls that have ever used any injectable 
contraceptives, the percentages related to injectable contraceptive use characteristics are small 
and thus, their sum are far less than 100%. 
** Injectable contraceptives use: women who used injectable contraceptives including those 
who also took oral contraception. 
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4.2 BIVARIATE ANALYSIS: 
 
Bivariate analysis examines the distribution of the exposure variables and other 
potential risk factors among cases and controls and most importantly, seeks to 
establish whether risk factors are associated with both the exposure and the outcome 
of interest at the 5% significance level. Only variables that met this latter condition 
were fitted in multivariate logistic regression models in order to measure the strength 
of the association between hormonal contraceptive use patterns and breast cancer. 
 
Table 6 shows the distribution of age group, age group at menarche, pregnancy status, 
age group at first birth, parity and age group at menopause among cases and controls. 
The table also illustrates any statistical association between the aforementioned 
factors and the risk of developing invasive breast cancer (5% significance level). The 
results show that invasive breast cancer is strongly statistically associated with age 
group (p<0.0001). The age distribution differed significantly between cases and 
controls, with cases being in the majority in age groups 30--49, while among controls, 
the highest proportions are found among younger and older age (below 30 and above 
60 years).The comparative age distribution of cases and controls is affected by the 
fact that the controls are not a sample of the background population but other recently 
diagnosed cancer cases, some of which occur in older or younger age groups than 
breast cancer cases. In addition, the distribution of age among breast cancer patients 
revealed a particular trend. The proportions of cases increase with age and attain the 
highest level at the age interval 40-49 and thereafter the proportions decrease with an 
increasing age.  This is supported by a non-parametric test for trend p value as shown 
in the table (p<0.0001). 
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Age at menarche, pregnancy status, age at first birth, parity and age at menopause 
were not statistically associated with breast cancer. 
Table 6: Reproductive characteristics among cases and controls 
 
 
Characteristics 
Types of cancer  
Total 
 
P value 
Breast cancer 
N (%) 
 
Controls 
N (%) 
Age 
 
15-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-75 
 
Age at Menarche 
10-14 
15-19 
≥20 
 
Ever pregnant? 
Yes 
No 
 
Age at first birth 
15-19 
20-29 
30-39 
40-49 
 
Parity 
0 
1-2 
3-5 
≥6 
 
Age at menopause 
28-39 
40-49 
≥50 
 
 
 
1(20.0) 
11(21.2) 
92(50.3) 
239(61.8) 
221(45.8) 
147(38.6) 
42(35.3) 
 
 
256(49.2) 
502(45.8) 
20(46.5) 
 
 
747(47.2) 
39(42.4) 
 
 
102(41.5) 
244(48.9) 
242(47.5) 
184(46.1) 
 
 
14(56) 
205(48) 
179(42.7) 
51(39.2) 
 
 
22(47.8) 
192(43.6) 
222(41.7) 
 
 
 
 
4(80.0) 
41(78.8) 
91(49.7) 
148(38.2) 
262(54.2) 
234(61.4) 
77(64.7) 
 
 
264(50.8) 
595(54.2) 
23(53.5) 
 
 
836(52.8) 
53(57.6) 
 
 
144(58.5) 
255(51.1) 
267(52.5) 
215(53.9) 
 
 
11(44) 
220(51.8) 
240(57.3) 
79(60.8) 
 
 
24(52.2) 
248(56.4) 
310(58.3) 
 
 
 
 
5 
52 
183 
387 
483 
381 
119 
 
 
520 
1097 
43 
 
 
1583 
92 
 
 
246 
499 
509 
399 
 
 
25 
425 
419 
130 
 
 
46 
440 
532 
 
 
<0.0001 
<0.0001* 
 
 
 
 
 
 
 
 
0.426 
 
 
 
 
0.370 
 
 
 
0.275 
 
 
 
 
 
0.130 
 
 
 
 
 
0.654 
 
 
 
 
* The p value of a non-parametric test for trend 
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Table 7 shows a bivariate analysis of socio-demographic characteristic among cases 
and controls. Concerning education level, a strongly significant association between 
years of schooling and the occurrence of breast cancer is demonstrated, (p<0.0001).A 
total of 451women had education levels less than or equal to 7 years of education; of 
which 174(38.6%) had breast cancer. Of 685 women who had education level 
between 8 and 11 years of education, 319(46.6%) were cases. Out of 469 women who 
had greater than or equal to 12 years of education, 259(55.2%) had breast malignancy. 
Therefore, the largest proportion of women diagnosed with invasive breast cancer had 
an educational level greater than or equal to12 years of schooling.  A non-parametric 
test for trend (p<0.0001) supports a trend of increasing proportions of breast cancer 
cases with increasing level of education.  
  
Smoking appeared to be associated with breast cancer (p=0.007) in the bivariate 
analysis. The association is probably due to confounding with use of hormonal 
contraceptive. Out of 1261 women who had never smoked, 613(48.6%) developed 
breast cancer. There were a total of 133 women who were current smokers and 
56(42.1%) of them developed cancer of the breast. Of the 208 women who had ever 
smoked in the past, 78(37.5%) developed cancer of the breast. This decreasing trend 
of proportions among breast cancer patients in relation with smoking status was 
supported by a non-parametric test, (p=0.003) 
 
Area of birth (rural vs urban) was also found to be statistically associated to the 
development of breast cancer among study participants (p=0.009). A slightly higher 
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proportion of breast cancer cases were born in urban areas (50.2%) compared to 
controls. Among rural born women, 43.6% were cases and 56.4% controls.  
 
Marital status, number of lifetime sexual partners and type of house were not 
statistically associated with breast cancer. 
 
Table7: Socio-demographic characteristics among cases and controls 
 
 
Characteristics 
Types of cancer  
Total 
 
P value 
Breast cancer 
N (%) 
 
Controls 
N (%) 
 
Years of education 
≤ 7 
8-11 
≥ 12 
 
Smoking status  
Never 
Current smoker 
Past smoker 
 
Place of birth 
Rural 
Urban 
 
Marital status 
Single 
Married 
Widowed 
Separated 
     
Number of sexual  
partners 
Single 
Multiple 
 
House made of: 
Other  materials 
Brick/cement 
 
 
 
 
174(38.6) 
319(46.6) 
259(55.2) 
 
 
613(48.6) 
56(42.1) 
78(37.5) 
 
 
352(43.6) 
393(50.2) 
 
 
206(49.6) 
329(46.9) 
169(43.4) 
82(47.4) 
 
 
 
93(44.1) 
668(48.1) 
 
 
126(47.2) 
661(46.8) 
 
 
 
277(61.4) 
366(53.4) 
210(44.8) 
 
 
648(51.4) 
77(57.9) 
130(62.5) 
 
 
455(56.4) 
388(49.8) 
 
 
209(53.4) 
372(53.1) 
219(56.4) 
91(52.6) 
 
 
 
118(55.9) 
722(51.9) 
 
 
141(52.8) 
750(53.2) 
 
 
 
 
451 
685 
469 
 
 
1261 
133 
208 
 
 
807 
781 
 
 
415 
701 
388 
173 
 
 
 
221 
1390 
 
 
267 
1411 
 
<0.0001 
<0.0001* 
 
 
 
0.007   
0.003* 
 
 
 
0.009 
 
 
 
0.290 
 
 
 
 
 
 
0.378 
 
 
 
0.822 
* The p value of a non-parametric test for trend 
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Table 8 shows the distribution of socio-demographic characteristics that were earlier 
found to be significantly associated with breast cancer, among oral contraceptive 
users and non-users. It also seeks to demonstrate any statistical association between 
those factors (namely age group, education level, smoking status and place of birth) 
and the exposure variable under investigation.  
There is a strong statistical association between age group and oral contraceptive use 
(p<0.0001). Out of a total of three women aged 15-19, one (25%) used oral    
contraceptives. Of 50 respondents aged 20-29, 19 (38%) used oral contraceptives. 
Among 180 women in the age group 30-39, 63 (35%) were oral contraceptive users. 
In the age interval 40-49, there was a total number of 385, 145 (37.7%) of whom used 
oral contraceptives. There were 106 (22.1%) out of 479 respondents, aged 50-59 years 
who used oral contraceptives. In summary, Table 8 shows that the highest proportions 
of oral contraceptive use were found among women between 20 and 49 years of age. 
In contrast from age 50, the results show a decreasing trend of proportions of oral 
contraceptive users among study participants. This is strongly supported by a non-
parametric test for trend, (p<0.0001) 
Level of education was strongly significantly associated with oral contraceptive use, 
(p<0.0001). The use of oral hormonal contraceptives increases with the increasing 
level of education. This is supported by a non-parametric test for trend (p<0.0001). 
Among 446 study participants who had up to 7 years of education, 9.6% were OC 
users. Out of 679 women who had between 8 and 11 years of education, 22.5% used 
OC. Of 467 women who reached 12 years of schooling or higher level, 38.3% used 
OC. 
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Smoking status and area of birth were also significantly associated with oral 
contraceptive use (p<0.0001). Women who had never smoked constituted the highest 
proportion among oral contraceptives users (26.3%), while those who were currently 
smokers represented the lowest proportion (p<0.0001 in non-parametric test for 
trend). The proportion of oral contraceptive users was significantly higher in urban 
than in rural born women, 29.4% and 18.2, respectively (p<0.0001). 
 
Table 8: Oral contraceptives use and socio-demographic characteristics of 
interest among cases and controls 
 
 
Characteristics 
Oral contraceptive use  
Total 
 
P value 
Yes 
N (%) 
 
No 
N (%) 
Age 
 
15-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-75 
 
Years of education 
 
≤7 
8-11 
≥12 
 
Smoking status 
 
Never 
Current smoker 
Past smoker 
 
Place of birth 
 
Rural 
Urban 
 
  
 
 
1(25.0) 
19(38.0) 
63(35.0) 
145(37.7) 
106(22.1) 
36(9.5) 
5(4.2) 
 
 
 
43(9.6) 
153(22.5) 
179(38.3) 
 
 
 
328(26.3) 
21(15.8) 
24(11.5) 
 
 
 
146(18.2) 
228(29.4) 
 
 
 
 
3(75.0) 
31(62.0) 
117(65.0) 
240(62.3) 
373(77.9) 
344(90.5) 
113(96.9) 
 
 
 
403(90.4) 
526(77.5) 
288(61.7) 
 
 
 
921(73.7) 
112(84.2) 
184(88.5) 
 
 
 
656(81.8) 
547(70.6) 
 
 
 
 
4 
50 
180 
385 
479 
380 
118 
 
 
 
446 
679 
467 
 
 
 
1249 
133 
208 
 
 
 
802 
775 
 
 
<0.0001 
<0.0001* 
 
 
 
 
 
 
 
 
<0.0001 
<0.0001* 
 
 
 
 
<0.0001 
<0.0001* 
 
 
 
 
<0.0001 
* The p value of a non-parametric test for trend 
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Table 9 below describes socio-demographic characteristics of interest among IC users 
and non IC users and aims to show any statistical association between age, education 
standard, smoking status, place of birth and the exposure variable, IC use. 
 
 Age is strongly associated with injectable contraceptive use (p<0.0001). Women in 
this study population used ICs from an early age (75% of 18 to 19 year olds), and the 
use decreased after 39 years to reach the lowest proportion of use at the age interval 
70 to 75 years where users represent only one percent (p<0.0001 in non-parametric 
test for trend).  
 
As with OC use, education standard was also strongly statistically associated with 
injectable contraceptive use, (p<0.0001). Among 445 women who had seven years of 
schooling or less, 15.3% were IC users. Of 678 women who had between 8 and 11 
years of education, 27.1% used IC while out of 466 women who attained 12 or more 
years of schooling, 41.8% were IC users. Thus the use of injectable hormonal 
contraceptives increases with increasing level of education, as supported by a non-
parametric test for trend (p<0.0001). 
Smoking status and area of birth were also strongly associated with injectable 
contraceptive use (p<0.0001 and p=0.027, respectively). In addition, smoking status 
and area of birth showed trends similar to those noted among OC users. Thus the 
highest proportion of IC use occurred among those who had never smoked (30.9%), 
followed by current smokers (18.9%), and then past smokers, among whom IC use 
was the lowest (16.9%). IC use was higher among those born in urban areas (30.8%) 
than those born in rural areas (25.9%).  
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Table 9: Injectable contraceptive use and socio-demographic characteristics 
among cases and controls 
 
 
Characteristics 
Injectable contraceptive use  
Total 
 
P value 
Yes 
N (%) 
No 
N (%) 
Age 
<20 
20-29 
30-39 
40-49 
50-59 
60-69 
70-75 
 
Years of education 
 
≤ 7 
8-11 
≥ 12+ 
 
Smoking status 
 
Never 
Current smoker 
Past smoker 
 
Place of birth 
 
Rural 
Urban 
 
             
 
3(75.0) 
30(60) 
116(64.4) 
168(43.9) 
106(22.2) 
23(6.1) 
1(0.9) 
 
 
 
68(15.3) 
184(27.1) 
195(41.8) 
 
 
 
385(30.9) 
24(18.1) 
35(16.9) 
 
 
 
206(25.9) 
239(30.8) 
 
 
1(25.0) 
20(40) 
64(35.6) 
215(56.1) 
372(77.8) 
357(94) 
117(99.1) 
 
 
 
377(84.7) 
494(72.9) 
271(58.2) 
 
 
 
862(69.1) 
109(81.9) 
172(83.1) 
 
 
 
592(74.2) 
536(69.2) 
 
 
 
 
4 
50 
180 
383 
478 
380 
118 
 
 
 
445 
678 
466 
 
 
 
1247 
133 
207 
 
 
 
798 
775 
 
<0.0001 
<0.0001* 
 
 
 
 
 
 
 
<0.0001 
<0.0001* 
 
 
 
 
<0.0001 
<0.0001* 
 
 
 
 
0.027 
 
 
 
* The p value of a non-parametric test for trend 
 
 
Table 10 presents the distribution of oral contraceptive use and its related 
characteristics among cases and controls. The table also shows any statistical 
association between oral contraceptive use characteristics and the development of 
breast cancer at the 5% significance level. The overall use of the oral contraceptive 
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method was strongly associated with the risk of developing breast cancer (p<0.0001). 
Out of 374 respondents who used oral contraceptives (the number includes women 
who used OC only as well as those who used IC in addition to OC), 221 (58.9%) had 
breast cancer and 153 (41.2%) presented with other cancer that was not of 
gynaecological origin.  
 
With respect to oral contraceptives use patterns, the findings show that at the 5% 
significance level, age at last use of OC was significantly associated with breast 
cancer (p=0.022). Out of 21 women who were aged between 14 and 19 when they 
stopped using OC, 15(71.4%) were breast cancer patients. Among 127 women who 
stopped the use of OC at the age between 20 and 29, 65(51.2%) presented with breast 
cancer. There were100 women who stopped the use of OC when they were aged 30 to 
39, and 59(59%) of them developed breast malignancy. Thirty five (72.9%) out of 48 
women who stopped the use of OC between 40 and 50 years, developed breast cancer.  
 
The time since first use of OC was also investigated. This is the period of time that 
elapsed between the first time when the patient used OC and the age when breast 
cancer was diagnosed. It was measured as the age at diagnosis of the cancer, minus 
the age at first use. A borderline significant association (5% level) was found between 
time since first use of OC and breast cancer (p=0.060). Breast cancer risk appears to 
increase with increasing time since first use. Among 21 women who had less than or 
equal to 4 years between the time they started using OC and the time breast cancer 
was diagnosed, nine (42.9%) developed breast cancer. Among 33 women of whom 
the time since first use of OC was 5 to 9 years, 15 (45.5%) were breast cancer 
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patients. Out of 282 women whose the time since their first use of OC and the 
diagnosis of breast cancer was 10 years and above 174 (61.7%) had breast cancer.  
 
In contrast, there was no significant association between age at first use of OC and 
cancer of the breast. Similarly, there was no association between the time since last 
use of OC and breast cancer. Time since last use is the period of time that elapsed 
between the last time that the patient used OC and the age when breast cancer was 
diagnosed. Thus, it was calculated as the age at diagnosis of the cancer, minus the age 
at last use. There was no association between the duration of use of OC and breast 
cancer.  Duration of use of oral pills was calculated as the difference between the age 
when women stopped the use of OC and the age when women started that 
contraceptive method.  
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Table 10: Patterns of oral contraceptives use among cases and controls 
 
 
Oral contraceptive use 
Characteristics 
Type of cancer  
Total 
 
P value 
Breast cancer 
N (%) 
Controls 
N (%) 
Oral 
contraceptive(OC) 
No 
Yes 
 
Age at first use of OC 
14-19 
20-29 
30-39 
40-50 
 
Age at last use of OC 
14-19 
20-29 
30-39 
40-50 
 
Time since first use of 
OC 
≤4 
5-9 
≥10 
 
Time since last use of 
OC 
≤4 
5-9 
≥10 
 
Duration of use of 
OC 
≤4 
5-9 
10-14 
15-19 
≥20 
 
 
 
528(43.2) 
221(59.1) 
 
 
51(60.7) 
95(55.2) 
48(67.6) 
4(50) 
 
 
15(68.2) 
65(51.2) 
59(59) 
35(72.9) 
 
 
 
9(42.9) 
15(45.5) 
174(61.7) 
 
 
 
30(57.7) 
28(59.6) 
121(59.3) 
 
 
 
92(56.1) 
45(52.3) 
29(64.4) 
23(71.9) 
15(65.2) 
 
 
 
 
 
693(56.8) 
153(40.9) 
 
 
33(39.3) 
77(44.8) 
23(32.4) 
4(50) 
 
 
6(28.6) 
62(48.8) 
41(41) 
13(27.1) 
 
 
 
12(57.1) 
18(54.5) 
108(38.3) 
 
 
 
22(42.3) 
19(40.4) 
83(40.7) 
 
 
 
72(43.9) 
41(47.7) 
16(35.6) 
9(28.1) 
8(34.8) 
 
 
 
 
 
1221 
374 
 
 
84 
172 
71 
8 
 
 
21 
127 
100 
48 
 
 
 
21 
33 
282 
 
 
 
52 
47 
204 
 
 
 
164 
86 
45 
32 
23 
 
 
 
 
<0.0001 
 
 
 
0.314 
 
 
 
 
 
0.022 
 
 
 
 
 
 
0.060 
 
 
 
 
 
0.975 
 
 
 
 
 
0.271 
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Table 11 illustrates the distribution of injectable contraceptive use and its related 
characteristics among cases and controls and highlights IC use characteristics that are 
statistically associated with breast cancer. The overall use of injectable contraceptives 
was strongly associated with the risk of developing breast cancer (p<0.0001). Out of 
446 women who used the IC method (alone or in conjunction with OCs), 244 (54.6%) 
developed breast cancer and 202 (45.4%) did not. There was also an association 
between the use of both hormonal contraceptive methods and the occurrence of breast 
cancer (p<0.004). Of 185 women who used both oral and injectable contraceptive 
methods, 105(56.8%) developed breast cancer and 79(43.2%) presented with other 
types of cancers not of gynaecological origin.  
 
Age at first use of IC was significantly associated with cancer of the breast (p=0.018). 
Proportions of breast cancer among this study population tend to increase with an 
increasing age at first use of IC (p=0.019 in non parametric test). Among 99 women 
who were aged between 14 to19 when they started using injectable contraceptives, 43 
(43.4%) developed breast cancer. Of 204 women who started the use of IC at the age 
interval 20-29, 119 (58.3%) were breast cancer patients. Among 91women who 
started using injectable hormonal contraception between ages 30 to 39, 50 (55.4%) 
were breast cancer patients. Out of 21 women who started injectable contraceptives 
when they were aged 40 years and above, 16 (76.2%) developed breast cancer.  
 
Age at last use of IC was also significantly associated with breast cancer at the 5% 
level (p=0.045). Out of 23 women who were aged between 14 and 19 when they 
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stopped using IC, 11 (45.8%) were breast cancer patients. Among 133 women who 
stopped the use of IC between 20 and 29 years of age, 63 (47.4%) presented with 
breast cancer. There were123 women who stopped the use of IC when they were 
between30 and 39 years of age, and 78 (63.4%) of them developed breast malignancy. 
Therefore, proportions of breast cancer patients tend to increase with an increasing 
age at last use of injectable contraceptive method, up to age 39 (p=0.021 in non-
parametric test). 
 
A borderline statistical association (5% significance level) was found between the 
duration of use of IC and breast cancer, (p=0.060) and, surprisingly there was no 
significant trend of proportions of breast cancer cases observed with regard to the 
duration of use of IC (p=0.157 in a non-parametric test). Nevertheless, the proportion 
of breast cancer cases increased from 5 to 19 years of use of IC. Among 218 women 
who used injectable contraceptives for a period of 4 years or less, 119 (54.6%) of 
them had breast cancer. Out of 93 women who used IC for a period of 5 to 9 years, 44 
(47.3%) developed breast cancer. Twenty nine (67%) out of 43 women who used IC 
for a period of 10 to 15 years, had breast cancer. Among 32 women who used IC for 
duration of 15 to 19 years, 23 (71.9%) developed breast cancer. Of 17 women who 
used IC for a period of 20 years and above, 8 (47.1%) of them had breast cancer.  
There was no statistical association between the time since first use of IC and breast 
cancer at the 5% significance level. Similarly, no significant association was 
demonstrated between the time since last use and breast cancer.  
 
 
 
 44
 
Table11: Patterns of injectable contraceptives use among cases and controls 
 
 
Hormonal use 
Characteristics 
Type of cancer  
Total 
 
P value 
Cases 
N (%) 
 
Controls 
N (%) 
 
Injectable 
contraceptive(IC) 
No 
Yes 
 
Injectable and oral 
contraceptive(OCIC) 
No 
Yes 
 
Age at first use of IC 
14-19 
20-29 
30-39 
40-50 
 
 
Age at last use of IC 
14-19 
20-29 
30-39 
40-50 
 
Time since first use of 
IC 
≤4 
5-9 
≥10 
 
Time since last use of 
IC 
≤4 
5-9 
≥10 
 
Duration of use of IC 
 
≤4 
5-9 
10-14 
15-19 
≥20 
 
 
 
 
 
502(43.8) 
244(54.6) 
 
 
 
640(45.5) 
105(56.8) 
 
 
43(43.4) 
119(58.3) 
50(55) 
16(76.2) 
 
 
 
11(45.8) 
63(47.4) 
78(63.4) 
46(59.7) 
 
 
 
14(48.3) 
23(45.1) 
191(56.8) 
 
 
 
57(55.9) 
29(59.2) 
112(54.9) 
 
 
 
119(54.6) 
44(47.3) 
29(67) 
23(71.9) 
8(47.1) 
 
 
 
644(56.2) 
202(45.4) 
 
 
 
765(54.5) 
80(43.2) 
 
 
56(56.6) 
85(41.7) 
41(45) 
5(23.8) 
 
 
 
12(54.2) 
70(52.6) 
45(36.6) 
29(40.3) 
 
 
 
15(51.7) 
28(54.9) 
145(43.2) 
 
 
 
45(44.1) 
20(40.8) 
92(45.1) 
 
 
 
99(45.4) 
49(52.7) 
14(32.6) 
9(28.1) 
9(52.9) 
 
 
 
 
1146 
446 
 
 
 
1405 
185 
 
 
99 
204 
91 
21 
 
 
 
23 
133 
123 
75 
 
 
 
29 
51 
336 
 
 
 
102 
49 
203 
 
 
 
218 
93 
43 
32 
17 
 
 
<0.0001 
 
 
 
 
0.004 
 
 
 
0.018 
 
 
 
 
 
 
0.041 
 
 
 
 
 
 
0.223 
 
 
 
 
 
0.863 
 
 
 
 
0.060 
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4.3 MULTIVARIATE ANALYSIS  
 
 
Unadjusted and adjusted odds ratios with associated 95% confidence intervals were 
obtained from univariate and multivariate logistic regression models by considering 
the type of cancer (breast cancer vs controls) as the outcome variable. The exposures 
under investigation were oral contraceptive method used exclusively, injectable 
contraceptive use exclusively, combined oral and injectable contraceptive use and 
their related characteristics that were found in the bivariate analyses to be statistically 
significantly associated with breast cancer. In addition, hormonal contraceptive use 
patterns for which p values were slightly higher than the 5% significance level in the 
bivariate analysis were assessed in multivariate analysis in order to determine the 
strength of their association with breast cancer. In assessing the measure of effect 
(OR) associated with time since last use of OC and time since first use of OC, the 
multivariate analysis was restricted to women who used OC exclusively. Similarly, in 
order to precisely measure the strength of effect associated with age at first use of IC, 
age at last use of IC, the multivariate analysis was limited to study participants who 
used IC only. The justification of this separate analysis was that an effect modification 
(interaction) was first investigated and found between OC use and IC use in the 
development of breast cancer. 
 
Reproductive and socio-demographic characteristics that were found in the bivariate 
analyses to be statistically associated with the outcome and the exposure variable 
were considered and fitted into the logistic regression models. These risk factors 
were: age, level of education, smoking status and place of birth.  
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At the 5% level of significance, both unadjusted and adjusted odds ratios obtained by 
univariate and multivariate logistic regression models in Table 12 below show that, 
after adjusting for independent risk factors, oral contraceptive use was associated with 
the risk of developing breast cancer. Women who used OC exclusively were two 
times more likely to develop breast cancer than those who never used any hormonal 
contraceptive method (OR: 1.92, 95%CI: 1.45, 2.80, p<0.0001). 
 
Women who had used injectable contraceptives exclusively were 1.5 times more 
likely to present with breast cancer than study participants who never used any 
hormonal contraception during their fertile period (OR: 1.51, 95%CI: 1.14, 2.01, 
p=0.008). Women who used both injectable and oral contraception were roughly 1.7 
times more likely to develop breast cancer than those who did not use any hormonal 
contraceptive method (OR: 1.68, 95% CI: 1.21, 2.33, p=0.004). There was strong 
effect modification between OC and IC use (p=0.008). This means that the effect of 
oral hormonal contraceptives on breast cancer decreases if women also used 
injectable contraceptives (from OR: 1.92 to 1.68). In contrast, the risk associated with 
IC goes up if women also took oral contraception (from OR: 1.51 to OR 1.68). 
 
Education standard was the only socio-demographic factor found to be associated 
with the risk of breast cancer in the logistic regression model. After controlling for 
contraceptive use, age, smoking status and area of birth, women who had between 8 
and 11 years of education had a 1.3 times higher risk of developing breast cancer than 
women who had less than or equal to seven years of schooling ;OR:1.3 ,95% CI 
0.97,2.80, p=0.076). 
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Those with an education level greater than or equal to 12 years were 1.6 times more 
likely to develop breast malignancy compared to women who had seven years of 
education or less; OR:1.6,95%CI: 1.20,2.10 ,(p=0.001). Thus, there is evidence that 
the risk of cancer of the breast increases with increasing level of education (non-
parametric test for trend; p<0.0001) 
 
The association between hormonal contraceptives use and breast cancer stratified by 
education level (Mantel Haenszel technique) showed crude OR: 1.89, 95%CI: 1.47, 
2.39, and adjusted (combined) OR: 1.6, 95%CI: 1.36, 2.09 (p<0.00001). Further 
analysis showed that the effect of hormonal contraceptive use on breast cancer can be 
treated as homogenous over the three education strata (test of homogeneity: 
p=0.1676). Therefore, the stratified analysis by combined Mantel-Haenszel method 
and its associated test of homogeneity revealed that education level was confounding 
the association between hormonal contraceptive use and breast malignancy. Thus 
education attainment was a confounding factor and not an effect modifier. After 
adjusting (stratification) for education level, the combined Mantel-Haenszel estimate 
of OR 1.7 (95%CI: 1.36, 2.09, p<0.00001) meant that a woman who used hormonal 
contraceptives is 1.7 times more at risk of developing breast cancer compared to 
women who never used hormonal contraception. 
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TABLE12: LOGISTIC REGRESSION ANALYSIS OF THE RISK OF BREAST CANCER IN 
RELATION TO EXPOSURE TO HORMONAL CONTRACEPTIVES 
 
 
OR and 95% confidence interval unadjusted and adjusted for age (continuous), level of education, 
smoking status, area of birth  
* The p value of a non-parametric test for trend 
Hormonal Contraceptive Use 
Related Characteristics 
Univariate (Unadjusted) Multivariate (Adjusted) 
Odds Ratio (95%C.I) P value Odds Ratio (95% C.I) P value 
Contraceptive use 
Never  
Exclusively OC use 
Exclusively IC use 
Combined OC&IC  
Age at last use of OC 
14-19 
20-29 
30-39 
40-50 
Time since first use of OC 
≤4 
5-9 
≥10 
Age at first use of IC 
14-19 
20-29 
30-39 
40-50 
Age at last use of IC 
14-19 
20-29 
30-39 
40-50 
Age 
15-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-75 
Years of education 
≤ 7 
8-11 
≥ 12 
Smoking status 
Never 
Past smoker 
Current smoker 
Place of birth 
Rural 
Urban 
 
 
 
 
 
 
1 
2.26 (1.64 , 3.12) 
1.65 (1.25, 2.18) 
1.92 (1.39,2.64) 
 
1 
0.60 (0.28,1,28) 
1.5 (0.56,3.98) 
1 (0.83,11.93) 
 
1 
1.11(0.38,3.34) 
2.14(0.87,5.26) 
 
1 
1.85(1.14,3.01) 
1.61(0.91,2.86) 
4.24(1.44,12.48) 
 
1 
1.06(0.44,2.54) 
2.04(0.84,4.95) 
1.75(0.68, 4.48) 
 
1 
1.07(0.10,10.59) 
4.04(0.44,36.87) 
6.46(0.71,58.34) 
3.37(0.37,30.4) 
2.51(0.27,22.70) 
2.18(0.23,20.15) 
 
1 
1.38(1.08,1.76) 
1.96(1.50,2.55) 
 
 
1 
0.85(0.52,1.28) 
1.30(0.90,1.86) 
 
 
1 
1.30(1.06,1.58) 
 
 
< 0.0001 
<0.0001 
<0.0001 
 
 
0.192 
0.427 
1.000 
 
 
0.851 
0.095 
 
 
0.012 
0.100 
0.009 
 
 
0.890 
0.111 
0.243 
 
 
0.952 
0.215 
0.097 
0.278 
0.412 
0.492 
 
 
0.008 
<0.0001 
 
 
 
0.396 
0.154 
 
 
 
0.009 
 
1 
1.92 (1.45 , 2.80) 
1.51 (1.14, 2.01) 
1.68 (1.21, 2.33) 
 
1 
0.56(0.25,1.23) 
1.15(0.38,3.42) 
0.87(0.06,10.92) 
 
1 
0.42(0.06,2.98) 
1.13(0.21,6.1) 
 
1 
1.37(0.74,2.53) 
1.47(0.65,3.31) 
4.38(0.84,22.83) 
 
1 
0.39(0.12,1.27) 
1.18(0.37,3.75) 
0.78(0.21,2.79) 
 
1 
0.86(0.08,9.30) 
3.44(0.34,34.13) 
6.99(0.70,69.13) 
4.24(0.43,42.44) 
3.60(0.36,35.97) 
3.21(0.31,32.82) 
 
1 
1.3(0.97,2.80) 
1.6(1.20,2.10) 
 
 
1 
0.83(0.53,1.31) 
1.14(0.78,1.66) 
 
 
1 
1.18(0.96,1.46) 
 
 
<0.0001 
0.008 
0.004 
 
 
0.151 
0.800 
0.914 
 
 
0.390 
0.883 
 
 
0.308 
0.348 
0.079 
 
 
0.121 
0.778 
0.705 
 
 
0.907 
0.291 
0.096 
0.214 
0.274 
0.325 
 
 
0.076 
0.001 
<0.0001* 
 
 
0.439 
0.476 
 
 
 
0.112 
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CHAPTER FIVE: DISCUSSION 
 
 
Injectable hormonal contraceptives, especially DMPA (trade name Depo-Provera) and 
to a greater extent, combined estrogen/progestogen oral contraceptives have been 
subjected to repeated epidemiologic assessment of breast cancer risk since sex 
hormones as contraceptives began in 1960.6,8,27,28,29,30,31,32,33 In contrast to many 
published studies relating hormone replacement therapy to increased risk of breast 
cancer in post-menopausal women, the association between contraceptive hormones 
and breast cancer has not yet been resolved.6,8,34,35,36,37  On the African continent, 
epidemiological investigations to assess the role of hormonal contraceptives in the 
increasing incidence of breast cancer among African women are rare. A case control 
study, in which cases of breast cancer (n=419) and controls (n=1,625), was carried out 
in the Western Cape from 1994 to 1997.6 The findings suggested a non significant 
relative risk associated with injectable progestogen contraceptives: RR: 0.9 (95%CI 
0.7, 1.2, including the null value:1), while an overall increased risk was found in 
association with oral contraceptive use (relative risk 1.2, 95% CI 1.1, 1.5).  
 
The present research report is based on an ongoing case control study undertaken by 
the MRC/Wits/NHLS Cancer Epidemiology Research Group at tertiary hospitals in 
Gauteng. The study includes 753 women diagnosed with breast cancer and 855 
controls. Cases and controls did not show any significant difference with regard to 
characteristics that are normally associated with the risk of developing breast cancer. 
The mean age of cases and controls were 51.5 and 53.3 respectively while the median 
age of cases and controls were 51 and 55 years, respectively. Our study participants 
were older than those described in a study aimed at describing hormonal contraceptive 
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use patterns among black and coloured South African women. The investigation that 
was carried out in the Western Cape reported median age of cases and controls of 43 
and 42 years, respectively.8   The older age among participants in this study is due to 
the fact that they were all cancer patients. Surprisingly, in our study, reproductive 
characteristics such as age at menarche, age at first birth, parity and age at menopause 
did not show any significant difference among cases and controls. Similarly, socio-
demographic factors normally associated with breast cancer in other studies, such as 
area of residence (urban/rural) and smoking status showed no significant difference 
between cases and controls. In the comparison of means/proportions, the only 
sociodemographic characteristics that appeared to be significantly different between 
cases and controls were age and education level. 
 
With regard to hormonal contraceptive use characteristics, proportions of cases and 
controls that used oral pills were significantly different. The trend was also observed 
among cases and controls who used either injectable contraception alone or both 
hormonal methods. On the contrary, there was no significant difference in the 
distribution between cases and controls in the following characteristics that are related 
to either hormonal contraceptive method: age at starting use, age at last use, time 
since first use, time since last use and duration of use. 
 
The bivariate analysis conducted in this study shows that at the 5% significance level, 
breast cancer is statistically significantly associated with the following reproductive 
and socio-demographic characteristics: age, education level, smoking status and place 
of birth. In our dataset, contrary to findings in the medical literature, age at menarche 
was not associated with breast cancer. Similarly, age at first child birth was also not 
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found to be associated with breast cancer, in contrast to other studies. Finally, in 
contrast to the breast cancer literature, parity was also not found to be associated with 
breast cancer in our investigation, and was therefore not considered for further 
analysis. 
 
 In this investigation, the non-existence of association between well-known risk 
factors and breast cancer may be due to selection, information and/or measurement 
bias in the study design and conduct. Cases and controls were selected from the same 
hospitals because it was easier to access and recruit study participants. However, one 
must bear in mind that these controls may not be representative of the population 
(socioeconomic groups of black South African women) that produced the cases with 
regard to risk factors normally associated with breast cancer. For instance, a nun 
diagnosed with cancer other than gynaecological at these tertiary hospitals would not 
be an appropriate control for a multiparous domestic worker presenting with breast 
cancer at the same institutions. Therefore, it would have been better to use population-
based controls.     
 
 The analysis revealed that malignant breast cancer is associated with the use of oral 
contraception, injectable contraception, both oral and injectable contraceptive use, age 
at first use of IC and age at last use of IC. In contrast, age at first use of OC variable 
was not associated with breast cancer. Age at last use of OC variable showed a p 
value (p=0.050) that is at the borderline of 5% significance level and therefore was 
subsequently assessed in multivariate analysis. Time since first use and time since last 
use of each contraceptive method were not associated with breast cancer. The most 
likely reason for these results is that it is probably unlikely that women accurately 
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remember, and therefore accurately report, each time that they start and stop different 
methods of contraception. Thus there is likely to be some kind of reporting error. In 
the Apartheid era, women were sometimes injected with ICs at clinics without even 
being told or consulted about it. In addition, it is also possible that the 
microscopic/histological diagnosis of breast cancer among black South African 
women may have occurred at an advanced stage of the disease and therefore, its 
actual onset did not correspond with the time of confirmation by clinicians and 
pathologists. Thus, except for the time since first use of OC variable, that showed a 
slightly higher p value (p=0.060) than the significance level, other features of 
hormonal contraceptive use such as time since first use and time since last use of 
either oral or injectable contraceptives were not included in their respective 
multivariate regression models. Similarly, because duration of use of either hormonal 
contraceptive method was not available, age at first use subtracted from age at last use 
was used as a proxy measure, without taking into account possible interruptions and 
pregnancies. The fact that no association was found between duration of use of OC 
and IC and breast cancer may be a result of this being an inaccurate reflection of 
actual use.  However, given that the relationship between duration of use of IC and 
breast cancer showed a p value slightly higher than the 5% significance level 
(p=0.060), the variable was included in multivariate logistic regression model for 
further analysis. 
 
5.1 Risk of breast cancer in relation to the use of hormonal contraceptives 
Based on analysis at the 5% level of significance in univariate and multivariate 
logistic regression models, this study indicates that there is an increased risk for 
developing breast cancer associated with oral contraceptives. After adjusting for 
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independent risk factors, the strength of the association was OR: 2.0 (95%CI 1.45, 
2.80, p<0.0001). This finding shows a measure of effect that is much higher than an 
overall 1.2 fold increase associated with oral contraceptive use in a case control study 
conducted in greater Cape Town.6    However, the result in the current study is 
supported by the fact that both case control studies found an increased risk associated 
with oral contraceptive use. No other contraceptive use features were found to have 
statistically significant risk associated with breast cancer in multivariate regression 
analysis. This seems to be incompatible with the overall risk increase associated with 
oral contraceptive use, and contrasts with the findings of a world-wide meta-analysis 
that reported an increased risk of breast cancer among women using oral 
contraceptives for a longer duration.39, 40  Even age at last use of OC and time since 
first use of OC, included in the model because of their borderline significance level in 
the bivariate analysis, were not associated with breast cancer before and after 
adjusting for independent risk factors. This may be attributable to many reasons such 
as inappropriate selection of controls, poor recall of interruption in use of hormonal 
contraception (information bias) or a poor proxy measurement of certain variables. 
Information bias could have occurred if the cases recalled their contraceptive 
exposures better than the controls. It is likely that hormonal contraceptive users may 
be more aware of the possible role of the contraceptive method in the development of 
breast cancer. However, our results corroborate the findings of the greater Cape Town 
study. The latter also showed non- significant relative risks (RR) associated with 
interval since first use, interval since last use and duration of use of oral 
contraceptives.6    These results were found in the Cape Town study despite a much 
more detailed questionnaire than the current study with regard to patterns of usage, 
e.g. interruptions in use (L Stein, personal communication). 
 54
 
There is evidence derived from experiments on beagle dogs that unopposed 
progesterones, and more specifically Depo-Provera, may increase breast cancer risk.41 
However, many investigators believe that there is no risk in humans of developing 
breast malignant neoplasm that is associated with that contraceptive method.41, 42 In 
contrast, the present findings suggest that injectable contraceptive use increases the 
overall risk of developing breast cancer. Indeed, after adjusting for all confounders 
and other risk factors as identified in the bivariate analysis, the odds ratio was 1.51 
(95%CI: 1.14, 2.01, p=0.008). These results differ significantly from the findings of the 
greater Cape Town study that found a non-significant relative risk associated with IC 
use (OR 0.9 95%CI:0.7, 1.2: the confidence interval includes 1; the null value). 
Similarly, the results are not consistent with the findings of two epidemiological 
studies conducted in USA and in which no overall increase in the risk was found.43,44 
 
Our findings show that the injectable progestogens do not protect against breast 
cancer malignancy as has been suggested by their anti-oestrogenic activity. After 
adjusting for independent risk factors and excluding women who used, in addition, 
oral contraceptives, there were no other statistically significant results associated with 
IC use characteristics. These findings differ from the results of the greater Cape Town 
study that demonstrated an increased risk associated with the time since last use and 
the duration of use.6 However, the fact that there was no evidence of statistically 
significant findings associated with the time since last use and the duration of 
injectable contraceptives use may be the result of incorrect proxy measure used, or 
measurement bias related to these variables. For instance, the measurement of the 
duration of hormonal contraceptive use did not take into account possible 
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interruptions of hormonal contraceptive use due to pregnancies, possible change of 
contraceptive method or to absence of permanent sexual partners. 
 
In our investigation, the combined use of both injectable and oral contraceptives 
increase the risk of breast cancer (OR: 1.68. 95%CI: 1.21, 2.33, p=0.002). In addition, 
there was strong effect modification between oral and injectable contraceptive use in 
the development of breast cancer. This finding was the reason for which either 
contraceptive method was examined separately in multivariate analysis in order to 
precisely measure its associated risk. The fact that the risk associated with the use of 
both oral and injectable contraceptives does not show any multiplicative or additive 
pattern, as it would be statistically expected, may be attributable to the biological 
process underlying the role of oestrogen and progesterone in the development of 
breast malignancy. Indeed, there is no simple causal relationship between hormonal 
contraceptives and the development of breast cancer.   Rather, the pathogenesis of 
breast malignancy is the result of complex interaction of multiple factors; sex 
hormones (endogenous or exogenous), environment (socio-demographic 
characteristics) and genes (BRCA1 or BRCA2 mutations). All those factors are 
involved at different levels in the molecular pathways leading to malignant breast 
tumours.1, 9  
 
 Education level was associated with hormonal contraceptive use in the unadjusted 
bivariate analysis and was significantly associated with an increased risk for breast 
cancer. Therefore, education level was a confounding factor in the association 
between hormonal contraceptive use and breast cancer. South Africa is a society in 
transformation, particularly for the black South African population in general and 
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women in particular.38 The latter are indeed becoming more and more urban dwellers 
and more educated than before. This could mean that more women would be exposed 
as result of their high education attainment. However, the fact that education level is 
significantly associated with an increased risk for breast cancer does not imply a 
causal relationship. It may have merely occurred as a result of increased breast cancer 
awareness among black South African women who are more educated, or greater 
access to health care among the better educated. There may be other socio-economic 
factors such as diet, body mass index and obesity, related to socioeconomic status and 
education level that could shed light on the role of different socio-economic factors in 
the development of breast cancer. 
In our investigation, active smoking did not appear to be a risk factor for breast 
cancer. This finding corroborates the results of the Million Women Study.45 
 
5.2 Limitations  
The data for the present analysis was taken from an ongoing case control study, which 
was set up to look at the importance of suspected risk factors for all types of cancer. 
Therefore, the study was not specific to breast cancer. As a result, neither oral nor 
injectable contraceptive doses were accurately determined, and their composition as 
well as the duration and regularity of use were not clearly ascertained. In addition, 
information on some of the well known or suspected risk factors for breast cancer 
such as, duration of breastfeeding, family history and body mass index was not 
collected because data on these variables were not available. 
 Information on the type and dose of oestrogen and of progestagen in the hormonal 
contraceptive that our study participants have used was not ascertained. 
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 The investigation was based on a case control study that is prone to information 
(recall and measurement) bias and selection bias. Even though the study was hospital- 
based covering a wide catchment area, the selection of controls among other women 
suffering from cancers other than of gynaecological origin may be problematic, 
because cases and controls might have well-known as well as unidentified similar 
environmental and genetic risk factors: socio-economic factors and genetic mutations. 
 Lastly, the study did not focus on current hormonal contraceptive users because there 
was not enough data in the group. 
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CHAPTER SIX: CONCLUSIONS AND RECOMMENDATIONS 
 
This research report has provided strong evidence for three main conclusions 
applicable to Black South African women attending public hospitals: 
 
First, there is an overall increase in the risk of developing breast cancer for women 
who used oral contraceptives. The strength of the association between oral 
contraception and breast cancer appears to be real and not due to confounding or other 
independent risk factors because the latter were adjusted for. No other oral 
contraceptive use pattern was significantly associated with the risk of developing 
breast malignancy.  
 
Secondly, the use of injectable contraceptives increases the overall risk of developing 
breast malignant tumours. However, there was no evidence to suggest that the risk 
increased with injectable contraceptives use characteristics such as age at starting and 
stopping use, time since first and last use, and duration of use.  
 
Third, there was strong interaction between oral contraceptive use and injectable 
contraception in the development of breast cancer.  
 
Fourth, based on the bivariate and multivariate analyses, there was strong evidence 
that education level was associated with the exposure and was independently 
significantly associated with the risk of developing breast cancer. Therefore, 
education level was confounding the association between hormonal contraceptive use 
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and breast cancer. Whether this finding reflect the reality or is a result of bias may be 
a subject of further investigations, however the overall increased risk associated with 
hormonal contraceptives use in our findings suggests that more attention be paid in 
choosing contraceptive method. 
 
In general, the findings of this study can be used as basis for a number of policy 
recommendation related to existing prevention and control strategy of breast cancer 
among black South African women.  Firstly, of the findings should form part of 
public health education awareness campaigns about all potential risk factors for breast 
cancer. Secondly, given the increased risks, black South African women who use 
hormonal contraceptives and oral contraceptives in particular, should undergo regular 
mammography screening for breast cancer. 
 
Finally, considering the fact that the study design was not specific to breast cancer 
and consequently some relevant information was not collected or was measured by 
poor proxy, I would recommend that another more specific case control study that 
would include even black South African women using private health care facilities, be 
undertaken in the Johannesburg area. Similarly, the role of well known breast cancer 
risk factors such as parity, breast-feeding and body mass index in the development of 
breast cancer among black south African women should be considered for further 
research.8,40 
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